Eriksson B M, Wirgart B Z, Claesson K, Tufveson G, Magnusson G, Tötterman T, Grillner L
Department of Infectious Diseases, University Hospital, Uppsala, Sweden.
Clin Transplant. 1996 Dec;10(6 Pt 1):494-502.
Eighty-five renal transplant recipients were prospectively monitored for CMV infection up to 4 months post-transplantation by virus isolation from leukocytes, CMV antigen detection (pp65) in peripheral blood leukocytes (PBL), polymerase chain reaction (PCR) of alkaline treated plasma (P-PCR), PCR of extracted DNA from PBL (L-PCR) and serology. Additionally univariate and multivariate analyses of risk factors for patient and graft survival up to 4 yr post-transplantation were performed. The incidence of CMV infection was 78% and of CMV disease 33%. Antigen detection in PBL was positive before or at onset of symptoms in 23/24 (96%) evaluable patients with CMV disease. The corresponding figures for virus isolation were 22/24 (92%), P-PCR 21/24 (88%) and for L-PCR 18/24 (75%). The percentage of negative samples in patients without CMV disease was 89% for the antigen test, 92% for L-PCR and 83% for virus isolation and P-PCR. One rapid test (antigen test, P-PCR or L-PCR) was positive at a median of 16 d before the onset of symptoms. The antigen test was generally the first rapid test to become positive. CMV disease did not affect graft survival in the multivariate analysis but was associated with decreased patient survival.
对85名肾移植受者进行前瞻性监测,直至移植后4个月,通过从白细胞中分离病毒、检测外周血白细胞(PBL)中的巨细胞病毒抗原(pp65)、碱性处理血浆的聚合酶链反应(P-PCR)、从PBL中提取DNA的PCR(L-PCR)以及血清学方法来监测巨细胞病毒感染情况。此外,还对移植后4年患者和移植物存活的危险因素进行了单因素和多因素分析。巨细胞病毒感染的发生率为78%,巨细胞病毒疾病的发生率为33%。在24例可评估的巨细胞病毒疾病患者中,23例(96%)在症状出现前或出现时PBL中的抗原检测呈阳性。病毒分离的相应数字为22/24(92%),P-PCR为21/24(88%),L-PCR为18/24(75%)。在无巨细胞病毒疾病的患者中,抗原检测阴性样本的百分比为89%,L-PCR为92%,病毒分离和P-PCR为83%。在症状出现前中位数16天时,一项快速检测(抗原检测、P-PCR或L-PCR)呈阳性。抗原检测通常是第一个呈阳性的快速检测。在多因素分析中,巨细胞病毒疾病不影响移植物存活,但与患者存活率降低有关。